Publications

2021
Martin AR, Atkinson EG, Chapman SB, Stevenson A, Stroud RE, Abebe T, Akena D, Alemayehu M, Ashaba FK, Atwoli L. Low-coverage sequencing cost-effectively detects known and novel variation in underrepresented populations. The American Journal of Human GeneticsThe American Journal of Human Genetics. 2021;108:656-668.Abstract
Summary Genetic studies in underrepresented populations identify disproportionate numbers of novel associations. However, most genetic studies use genotyping arrays and sequenced reference panels that best capture variation most common in European ancestry populations. To compare data generation strategies best suited for underrepresented populations, we sequenced the whole genomes of 91 individuals to high coverage as part of the Neuropsychiatric Genetics of African Population-Psychosis (NeuroGAP-Psychosis) study with participants from Ethiopia, Kenya, South Africa, and Uganda. We used a downsampling approach to evaluate the quality of two cost-effective data generation strategies, GWAS arrays versus low-coverage sequencing, by calculating the concordance of imputed variants from these technologies with those from deep whole-genome sequencing data. We show that low-coverage sequencing at a depth of ≥4× captures variants of all frequencies more accurately than all commonly used GWAS arrays investigated and at a comparable cost. Lower depths of sequencing (0.5–1×) performed comparably to commonly used low-density GWAS arrays. Low-coverage sequencing is also sensitive to novel variation; 4× sequencing detects 45% of singletons and 95% of common variants identified in high-coverage African whole genomes. Low-coverage sequencing approaches surmount the problems induced by the ascertainment of common genotyping arrays, effectively identify novel variation particularly in underrepresented populations, and present opportunities to enhance variant discovery at a cost similar to traditional approaches.
Abrha S, Christenson JK, McEwen J, Tesfaye W, Vaz Nery S, Chang AY, Spelman T, Kosari S, Kigen G, Carroll S. Treatment of tungiasis using a tea tree oil-based gel formulation: protocol for a randomised controlled proof-of-principle trial. BMJ Open [Internet]. 2021;11(7):e047380. WebsiteAbstract

Introduction Tungiasis (sand flea disease or jigger infestation) is a neglected tropical disease caused by penetration of female sand fleas, Tunga penetrans, in the skin. The disease inflicts immense pain and suffering on millions of people, particularly children, in Latin America, the Caribbean and sub-Saharan Africa. Currently, there is no standard treatment for tungiasis, and a simple, safe and effective tungiasis treatment option is required. Tea tree oil (TTO) has long been used as a parasiticidal agent against ectoparasites such as headlice, mites and fleas with proven safety and efficacy data. However, current data are insufficient to warrant a recommendation for its use in tungiasis. This trial aims to generate these data by comparing the safety and efficacy of a 5% (v/w) TTO proprietary gel formulation with 0.05% (w/v) potassium permanganate (KMnO4) solution for tungiasis treatment.Methods and analysis This trial is a randomised controlled trial (RCT) in primary schools (n=8) in South-Western Kenya. The study will include school children (n=88) aged 6–15 years with a confirmed diagnosis of tungiasis. The participants will be randomised in a 1:1 ratio to receive a 3-day two times a day treatment of either 5% TTO gel or 0.05% KMnO4 solution. Two viable embedded sandflea lesions per participant will be targeted and the viability of these lesions will be followed throughout the study using a digital handheld microscope. The primary outcome is the proportion of observed viable embedded sand fleas that have lost viability (non-viable lesions) by day 10 (9 days after first treatment). Secondary outcomes include improvement in acute tungiasis morbidities assessed using a validated severity score for tungiasis, safety assessed through adverse events and product acceptability assessed by interviewing the participants to rate the treatment in terms of effectiveness, side effects, convenience, suitability and overall satisfaction.Ethics and dissemination The trial protocol has been reviewed and approved by the University of Canberra Human Research Ethics Committee (HREC-2019-2114). The findings of the study will be presented at scientific conferences and published in a peer-reviewed journal.Trial registration numbers Australian New Zealand Clinical Trials Registry (ACTRN12619001610123); PACTR202003651095100 and U1111-1243-2294.

2020
Kibet Too Philemon KKK. Carbon dioxide gas sensing, capture, and storage potential of calcium oxide surface and single walled carbon nanotube: insights from ab initio simulation. Journal of Physics: Condensed Matter. 2020;32(24):245901.Abstract

Single walled carbon nanotube (SWCNT) and alkaline metal oxide have been identified as potential materials for management of CO2 emission. Yet the underlying operating mechanism is still not well understood, while an in-depth understanding would possibly lead to development of superior CO2 monitoring, capture, and storage devices. Here we present ab initio density functional theory calculations to provide a comprehensive description of CO2 gas interaction with SWCNT and CaO surface. In particular, our results revealed that CO2 is chemisorbed on CaO surface with negligible effect on electronic properties of the absorbent, while CO2 interaction with SWCNT can be categorized as physisorption interaction a process that can be easily reversed using thermal treating of the tube at 150 °C. Thus CaO is found to be ideal for long term storage of CO2 while SWCNT reported superior performance in CO2 sensing and capture. This work may guide the development of better devices based on CaO and SWCNT for CO2 sensing, capture, and storage.

Pages